Company
About Edgewise
Our Vision
Management Team
Board of Directors
Scientific Advisory Board
R & D
Our Pipeline
Clinical Trials
Areas of Focus
Scientific Presentations & Publications
News
Press Releases
Events
Investors
Patients & Families
Our Promise
Our Research
Clinical Trials
Community & Resources
Join Our Team
Contact
Company
About Edgewise
Our Vision
Management Team
Board of Directors
Scientific Advisory Board
R & D
Our Pipeline
Clinical Trials
Areas of Focus
Scientific Presentations & Publications
News
Press Releases
Events
Investors
Patients & Families
Our Promise
Our Research
Clinical Trials
Community & Resources
Join Our Team
Contact
Creating lifesaving medicines for rare muscle disorders
our vision
Improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company.
latest news
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program
Dec 8, 2020
READ MORE
Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy
Nov 11, 2020
READ MORE
Edgewise Therapeutics Appoints John Moore as General Counsel
Oct 29, 2020
READ MORE
Edgewise Therapeutics Appoints Behrad Derakhshan as Chief Business Officer
Oct 22, 2020
READ MORE
Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial Officer
Oct 16, 2020
READ MORE
Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation
Jul 8, 2020
READ MORE
Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer
Jun 17, 2020
READ MORE
Edgewise Therapeutics Closes $50 Million Series B Financing
Sep 17, 2019
READ MORE
READ ALL ›
learn about our pipeline
view pipeline
2021 © Copyright. Edgewise Therapeutics. All Rights Reserved.
Privacy Policy
|
Terms of Use
.